Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00116467 · ClinicalTrials.gov registry record · Phase 2
Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia
A Phase 2 study, sponsored by Cell Genesys.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT00116467: Completed Phase 2 study, sponsored by Cell Genesys.
NCT00116467 is a Phase 2 study that has completed, run by Cell Genesys. The registered enrollment target is 55 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (59% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00116467, a Phase 2 study, has completed, sponsored by Cell Genesys.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate clinical and laboratory safety associated with the administration of GVAX leukemia vaccine and to determine the feasibility of generation of GVAX leukemia vaccine in subjects with acute myelogenous leukemia (AML).
Interventions
- BIOLOGICAL GVAX leukemia vaccine (therapeutic cellular vaccine, GM-CSF producing)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2001-03 |
| Est. Completion | 2006-01 |
| Phase | Phase 2 |
What the finished NCT00116467 record still lists
NCT00116467 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (59% lower).
The record links to 0 conditions, and to 1 intervention - of which GVAX leukemia vaccine (therapeutic cellular vaccine, GM-CSF producing) is the first listed.
NCT00116467 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00116467 about?
NCT00116467 is a clinical study titled "Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia". The purpose of this study is to evaluate clinical and laboratory safety associated with the administration of GVAX leukemia vaccine and to determine the feasibility of generation of GVAX leukemia vaccine in subjects with acute myelogenous leukemia (AML).
What is the current status of trial NCT00116467?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2001-03. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00116467?
The interventions under investigation include: GVAX leukemia vaccine (therapeutic cellular vaccine, GM-CSF producing) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00116467?
This trial is sponsored by Cell Genesys, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00116467's enrollment target sits among peer trials
55 1153rd of 2000 higher than 841 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia